can you take semaglutide after tirzepatide Switching from to Tirzepatide: Is It a Good Idea? What happens when you combine

More striking: DEXA scans showed lean mass preservation in 89% of dual-therapy patients versus 71% in monotherapy patients

Boehncke WH, Schn MP

GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP receptor agonists (tirzepatide) do not directly cause muscle wasting

Potential clinical outcomes include: 5 Loss of lean body mass with reduced resting metabolic rate Compromised bone mineral density Anemia, fatigue, cognitive changes Impaired immune and antioxidant defenses Slowed detoxification capacity due to inadequate phytonutrient intake Such cumulative effects not only threaten physiological stability but also diminish patient satisfaction, adherence, and long-term therapeutic success

Retatrutide represents a promising development in the obesity pharmacotherapy landscape

We stand behind our products